1342.3 - Oncotype DX breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission)

Page last updated: 19 October 2016

Application Detail

Status

Open

Description of Medical Service

Oncotype DX is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.

Description of Medical Condition

Outside Australia, Oncotype DX is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.

Reason for Application

New MBS item

Medical Service Type

Investigative

Previous Application Number

1342.2

Associated Documentation

Application Form

-

PICO Confirmation

As per application 1342

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 275 KB)
Public Summary Document (Word 107 KB)

Meetings for this Application

PASC

-

ESC

9 - 10 June 2016

MSAC

28 - 29 July 2016